Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 1998

View Archived Issues

Company Profile: Nymox

Major innovations fuel R&D at Astra

Agents for chronobiological disorders synthesized at Glaxo

PKC modulators for proliferative disorders described by Georgetown U.

New AIDS therapies in development in Korea

Indole endothelin antagonists prepared at Pfizer

Antitumor and antiviral distamycin derivatives from Pharmacia & Upjohn

Flavopiridol analogues as inhibitors of cyclin-dependent kinases

BMS discloses new Taxol derivative

Phenylglycine derivatives with mGluR-antagonist activity disclosed by Lilly

Positive U.S. phase II results for Thymoglobulin in preventing kidney transplant rejection

Anti-TNF strategy in MS treatment should be reconsidered

Rate-independent profile of antiarrhythmic agent suggests improved therapeutic potential

BioMarin's lead enzyme replacement therapy enters clinical trials

New test for cardiovascular disease risk assessment from Myriad Genetics

FDA panel recommends approval of Verdia

In vivo efficacy reported for angiotensin II blocker

EUK-134 effective in animal model of stroke

Allelix: Q1 1998 highlights

Antihypertensive efficacy described for Novartis' dual ACE/NEP inhibitor

Phase II trials of Sibia's Parkinson's disease Rx begin

Japanese approval for Biora's periodontal disease product

Pacific's cancer immunotherapy proves highly effective in rat metastatic mammary tumor model

Vaccine delivery joint venture finalized by Endorex and Elan

Viragen seeks to become fully integrated blood products company

ACT evaluated in second phase I trial in HIV/AIDS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.